Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EBITDA (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed EBITDA for 13 consecutive years, with -$159.6 million as the latest value for Q1 2026.

  • For Q1 2026, EBITDA fell 254.13% year-over-year to -$159.6 million; the TTM value through Mar 2026 reached -$473.0 million, down 272.85%, while the annual FY2025 figure was -$358.5 million, 224.82% down from the prior year.
  • EBITDA hit -$159.6 million in Q1 2026 for Viking Therapeutics, down from -$157.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$15.9 million in Q3 2022 and bottomed at -$159.6 million in Q1 2026.
  • Average EBITDA over 5 years is -$46.1 million, with a median of -$22.9 million recorded in 2024.
  • Year-over-year, EBITDA grew 6.09% in 2024 and then plummeted 329.01% in 2025.
  • Viking Therapeutics' EBITDA stood at -$18.9 million in 2022, then dropped by 27.46% to -$24.1 million in 2023, then crashed by 57.07% to -$37.8 million in 2024, then crashed by 316.68% to -$157.7 million in 2025, then decreased by 1.21% to -$159.6 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at -$159.6 million, -$157.7 million, and -$90.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.